Insider filing · TVTX
Jula Inrig
EVP, Head of R&D & CMO
profile →
Travere Therapeutics, Inc.
TVTX · Healthcare · 74 filings in 24 months
ticker →
Jula Inrig sold $630K of Travere Therapeutics (TVTX)
Executed Dec 24 2025, disclosed Dec 29 2025, 5 days later.
Value, as filed
$630K
15,000 sh × $42.00
Executed
Dec 24 2025
the trade date, as filed
Disclosed
Dec 29 2025
5 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JIJula Inrig (EVP, Head of R&D & CMO) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Travere Therapeutics, Inc. (TVTX). The largest single filing was $2.8M of TVTX (44,274 sh across 3 lots, as filed), executed Sep 15.
The name
TVTXHealthcare · Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Jula Inrig in TVTX
TVTXSALE
Travere Therapeutics, Inc.
$2.8M44,274 sh across 3 lots
Exec Sep 15
Filed Sep 17 · 9:33 PM ET TVTXSALE Travere Therapeutics, Inc. $1.0M
22,174 sh across 2 lots
Exec May 4
Filed May 6 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $303K
7,215 sh × $41.93
Exec Apr 14
Filed Apr 15 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. $223K
6,956 sh × $32.12
Exec Feb 3
Filed Feb 3 · 5:30 PM ET